Acute pulmonary embolism: part II: risk stratification, treatment, and prevention.
暂无分享,去创建一个
[1] A. Turpie,et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.
[2] S. Goldhaber,et al. Acute Pulmonary Embolectomy: A Contemporary Approach , 2002, Circulation.
[3] P. Romano,et al. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. , 2000, Archives of internal medicine.
[4] W. Ageno,et al. Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism , 2003, Annals of Internal Medicine.
[5] P D Stein,et al. Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism. , 1995, Chest.
[6] M. Gent,et al. Comparison of Low-Intensity Warfarin Therapy With Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism , 2004 .
[7] O. Linder,et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. , 1997, The New England journal of medicine.
[8] K. Mcintyre,et al. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism , 2000, Vascular medicine.
[9] Samuel Z Goldhaber,et al. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) , 1999, The Lancet.
[10] J. Vandenbroucke,et al. Oral contraceptives and the risk of venous thrombosis. , 2001, The New England journal of medicine.
[11] U. Janssens,et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. , 1999, Circulation.
[12] F. Rosendaal,et al. Heritability of clotting factors and the revival of the prothrombotic state , 2002, The Lancet.
[13] C. Francis,et al. Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty , 2002, Annals of Internal Medicine.
[14] S. Schulman,et al. A Comparison of Six Weeks With Six Months of Oral Anticoagulant Therapy After a First Episode of Venous Thromboembolism , 1996 .
[15] Kenneth E Wood,et al. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. , 2002, Chest.
[16] P. Ravaud,et al. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. , 2000, JAMA.
[17] B. Lämmle,et al. Accuracy of d‐dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study , 2003, Journal of thrombosis and haemostasis : JTH.
[18] H. Büller,et al. Brain Natriuretic Peptide as a Predictor of Adverse Outcome in Patients With Pulmonary Embolism , 2003, Circulation.
[19] J. Hosking,et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. , 1997, Annals of surgery.
[20] F. Barral,et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. , 1998, The New England journal of medicine.
[21] S. Goldhaber,et al. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. , 2003, Circulation.
[22] D. Slosman,et al. Performance of Helical Computed Tomography in Unselected Outpatients with Suspected Pulmonary Embolism , 2001, Annals of Internal Medicine.
[23] J. Beckman,et al. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism , 2003, Thrombosis and Haemostasis.
[24] I. Durieu,et al. Comparison of 3 and 6 Months of Oral Anticoagulant Therapy After a First Episode of Proximal Deep Vein Thrombosis or Pulmonary Embolism and Comparison of 6 and 12 Weeks of Therapy After Isolated Calf Deep Vein Thrombosis , 2001, Circulation.
[25] M. Gent,et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.
[26] O. Hess,et al. Low Pro-Brain Natriuretic Peptide Levels Predict Benign Clinical Outcome in Acute Pulmonary Embolism , 2003, Circulation.
[27] M. Fishbein,et al. Acute pulmonary embolism: don't ignore the platelet. , 2002, Circulation.
[28] S. Goldhaber,et al. Arterial blood gas analysis in the assessment of suspected acute pulmonary embolism. , 1996, Chest.
[29] S. Rapaport,et al. Correction of Excessive Anticoagulation with Low-Dose Oral Vitamin K1 , 1997, Annals of Internal Medicine.
[30] R. Raschke,et al. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. , 1996, Archives of internal medicine.
[31] M. Gould,et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. , 1999, Annals of internal medicine.
[32] T. Perneger,et al. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention , 2002, The Lancet.
[33] K. Schulman,et al. Cost-effectiveness analyses. , 1995, The New England journal of medicine.
[34] S. Schulman,et al. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. , 2000, The New England journal of medicine.
[35] S. Goldhaber. Integration of catheter thrombectomy into our armamentarium to treat acute pulmonary embolism. , 1998, Chest.
[36] S. Schulman,et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.
[37] S. Goldhaber. Echocardiography in the Management of Pulmonary Embolism , 2002, Annals of Internal Medicine.
[38] R. Goldszer,et al. The critical pathways of an anticoagulation service. , 2003, Critical Pathways in Cardiology.
[39] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[40] W. Haire. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. , 2003, Current hematology reports.
[41] P. Ridker,et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. , 2003, The New England journal of medicine.
[42] S. Goldhaber,et al. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. , 2000, Chest.
[43] M. Prins,et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.
[44] M. Olschewski,et al. Importance of Cardiac Troponins I and T in Risk Stratification of Patients With Acute Pulmonary Embolism , 2002, Circulation.
[45] T. Perneger,et al. Predicting Adverse Outcome in Patients with Acute Pulmonary Embolism: A Risk Score , 2000, Thrombosis and Haemostasis.
[46] P. Cecchini,et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. , 2000, Circulation.
[47] P. Grenier,et al. Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study , 2002, The Lancet.
[48] K. Mann,et al. Oral Anticoagulation Thresholds , 2001, Circulation.
[49] C. Kessler,et al. Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate , 2002, Annals of Internal Medicine.
[50] U. Seligsohn,et al. Genetic susceptibility to venous thrombosis. , 2001, The New England journal of medicine.
[51] R. Crapo,et al. Single-breath carbon monoxide diffusing capacity. , 2001, Clinics in chest medicine.
[52] E. Braunwald,et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion , 1993, The Lancet.
[53] J. Douketis,et al. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials , 2001, The Lancet.
[54] M. Prins,et al. Single-Detector Helical Computed Tomography as the Primary Diagnostic Test in Suspected Pulmonary Embolism: A Multicenter Clinical Management Study of 510 Patients , 2003, Annals of Internal Medicine.
[55] olfgang,et al. HEPARIN PLUS ALTEPLASE COMPARED WITH HEPARIN ALONE IN PATIENTS WITH SUBMASSIVE PULMONARY EMBOLISM , 2002 .
[56] S. Goldhaber,et al. Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. , 2002, Journal of the American College of Cardiology.
[57] M. Prins,et al. An association between atherosclerosis and venous thrombosis. , 2003, The New England journal of medicine.
[58] S. Goldhaber,et al. Prognostic Role of Brain Natriuretic Peptide in Acute Pulmonary Embolism , 2003, Circulation.
[59] V. Kakkar,et al. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. , 2001, The New England journal of medicine.
[60] S. Goldhaber,et al. Laboratory thrombophilias and venous thromboembolism , 2002, Vascular medicine.
[61] F Lapostolle,et al. Severe pulmonary embolism associated with air travel. , 2001, The New England journal of medicine.
[62] M Gent,et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.
[63] S. Schulman,et al. A randomized, controlled, dose‐guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I , 2003, Journal of thrombosis and haemostasis : JTH.
[64] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[65] lexander,et al. Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer , 2002 .
[66] J. Bartholomew,et al. Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia , 2001, Circulation.
[67] M Gent,et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.
[68] Olle Linder,et al. A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .
[69] M Gent,et al. Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer , 2000, Thrombosis and Haemostasis.